Clinical trial · Observational
Magnetic Resonance Imaging and Spectroscopy of the Prostate
NCT00590993CI-TRIAL-00070750completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Past studies have shown that MRI is useful for staging prostate cancer. This study will use magnetic resonance spectroscopic imaging (MRSI) to obtain more information. MRSIs with MRIs help doctors locate prostate cancer and determine the extent of tumor before deciding on treatment. This study looks at structural and chemical properties of prostates in prostate cancer patients before and after treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI and MRSI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 1 - MRSI / MRI
- interventionNames
- Other: MRI and MRSI
Primary outcomes (1)
- measure
- Determine added value in combining MRSI and MRI in prostate cancer treatment
- timeFrame
- 3 hours
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * prostate cancer patients willing to undergo a MRI and MRSI exam Exclusion Criteria: * patients with prostate cancer and bone or lymph node metastasis * patients who can not have an MRI exam
References
Publications (0)
Data not yet available
No reference posted for this study.